$2.36
9.58% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Biomea Fusion Inc Stock price

$2.36
+0.73 44.79% 1M
-3.28 58.16% 6M
-1.52 39.18% YTD
-3.45 59.38% 1Y
-16.24 87.31% 5Y
-16.24 87.31% 10Y
-16.24 87.31% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.25 9.58%
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Key metrics

Market capitalization $88.67m
Enterprise Value $50.69m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-132.72m
Free Cash Flow (TTM) Free Cash Flow $-113.86m
Cash position $37.98m
EPS (TTM) EPS $-3.51
P/E forward negative
Short interest 39.71%
Show more

Is Biomea Fusion Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Biomea Fusion Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Biomea Fusion Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Biomea Fusion Inc forecast:

Buy
71%
Hold
29%

Financial data from Biomea Fusion Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
6% 6%
-
- Research and Development Expense 106 106
5% 5%
-
-131 -131
3% 3%
-
- Depreciation and Amortization 1.80 1.80
9% 9%
-
EBIT (Operating Income) EBIT -133 -133
3% 3%
-
Net Profit -129 -129
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biomea Fusion Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomea Fusion Inc Stock News

Neutral
GlobeNewsWire
one day ago
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
Neutral
GlobeNewsWire
about one month ago
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in adults with acute leukemia (AL) were selected for a poster presentation at the European Hematology Association (EHA) 2025 Congress, taking pl...
Neutral
GlobeNewsWire
about one month ago
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapy Biomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities...
More Biomea Fusion Inc News

Company Profile

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Head office United States
CEO Michael Hitchcock
Employees 112
Founded 2017
Website www.biomeafusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today